Gregory Wasson Net Worth

The estimated Net Worth of Gregory D Wasson is at least $248 Tysiąc dollars as of 5 June 2024. Mr. Wasson owns over 10,061 units of OptimizeRx Corp stock worth over $247,731 and over the last 10 years he sold OPRX stock worth over $0. In addition, he makes $0 as Director at OptimizeRx Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Wasson OPRX stock SEC Form 4 insiders trading

Gregory has made over 6 trades of the OptimizeRx Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,061 units of OPRX stock worth $73,244 on 5 June 2024.

The largest trade he's ever made was buying 15,000 units of OptimizeRx Corp stock on 7 August 2020 worth over $262,350. On average, Gregory trades about 915 units every 41 days since 2015. As of 5 June 2024 he still owns at least 34,029 units of OptimizeRx Corp stock.

You can see the complete history of Mr. Wasson stock trades at the bottom of the page.

Gregory Wasson biography

Gregory D. Wasson serves as Director of the Company. As president and CEO of Walgreens, Wasson led the company to record sales of $76.4 billion in 2014. He created significant shareholder value by completing game-changing mergers and acquisitions, leading complex organizational and structural change, assembling a diverse and high-performance senior leadership team, and establishing Walgreens as an industry leader. Wasson is largely credited for transforming the iconic 114-year-old domestic company into the first global pharmacy-led, health, well-being, and beauty enterprise via the successful merger with European-based Alliance Boots in 2015. Prior to being appointed president and CEO of the combined companies, Walgreens Boots Alliance, Wasson had risen through the ranks through a number of positions of increasing responsibility and executive leadership, starting as a Walgreens pharmacist technician in 1981.

What's Gregory Wasson's mailing address?

Gregory's mailing address filed with the SEC is C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM, MA, 02453.

Insiders trading at OptimizeRx Corp

Over the last 2001 years, insiders at OptimizeRx Corp have traded over $20,012,815 worth of OptimizeRx Corp stock and bought 258,753 units worth $1,128,145 . The most active insiders traders include Investment Company, Inc. Awm, Bradley Louis Radoff oraz David Harrell. On average, OptimizeRx Corp executives and independent directors trade stock every 32 days with the average trade being worth of $183,485. The most recent stock trade was executed by Patrick D Spangler on 5 June 2024, trading 10,061 units of OPRX stock currently worth $73,244.

What does OptimizeRx Corp do?

optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.

Complete history of Mr. Wasson stock trades at PNC Services Inc, Verizon Communications Inc oraz OptimizeRx Corp

OptimizeRx Corp executives and stock owners

OptimizeRx Corp executives and other stock owners filed with the SEC include:

• Stephen Silvestro,
  Chief Commercial Officer
• William Febbo,
  Chief Executive Officer, Director
• William J. Febbo,
  CEO & Director
• Stephen L. Silvestro,
  Chief Commercial Officer
• Miriam Paramore,
  President
• Douglas Baker,
  Chief Financial Officer
• Gus Halas,
  Chairman of the Board
• Lynn Vos,
  Independent Director
• Patrick Spangler,
  Independent Director
• James Lang,
  Independent Director
• Angelo Campano,
  Senior Vice President - Principal of Agency Channels
• Ron Both,
  Investor Relations
• Gregory Wasson,
  Director
• Todd Inman,
  Chief Technology Officer
• Maira Alejandra,
  Media Relations Mang.
• Todd Inman,
  Chief Technology Officer
• Andrew Jacob D'Silva,
  Sr. VP of Corp. Fin.
• Douglas P. Baker,
  Exec. VP of Fin. & Accounting
• Edward Stelmakh C.M.A., M.B.A., MBA,
  CFO & COO
• Rebecca Whitney,
  Sr. VP of Commercial Operations
• Terence J. Hamilton,
  Sr. VP of Pharma
• Sheryl Kearney,
  HR Mang.
• Marion K Odence-Ford,
  Gen. Counsel & Chief Compliance Officer
• Cathy Klema,
  Director
• Ellen O'connor Vos,
  Director
• Plc Wpp Luxembourg Gamma Th...,
  
• Investment Company, Inc. Awm,
  10% owner
• Bradley Louis Radoff,
  10% owner
• Jack T Pinney,
  Director
• Richard Kraniak,
  10% owner
• David Lester,
  Chairman of the Board
• David Harrell,
  Chief Executive Officer
• Terrence Hamilton,
  Vice President
• James M Brooks,
  SVP of Business Development
• Brian J Dillon,
  SR. VP OF PRODUCT & STRATEGY
• Brian Clark Mc Carthy,
  Chief Revenue Officer
• Marion Odence Ford,
  General Counsel and CCO
• Edward Stelmakh,
  CFO/COO
• Doug Besch,
  Chief Product Officer
• Theresa Greco,
  Chief Commercial Officer